Volume 2, Issue 2 (2021)

1. Selimova LM, Kalnina LB, Serebrovskaya LV, Ivanova LA, Gulyaeva AN, Nosik DN. [CYTOKINES DURING THE HUMAN IMMUNODEFICIENCY VIRUS INFECTION TYPE 1(HIV-1)]. Vopr Virusol. 2016;61(1):39-41.

2. Alfano M, Poli G. Cytokine and chemokine based control of HIV infection and replication. Curr Pharm Des. 2001;7(11):993- 1013. 

3. French MA, Cozzi-Lepri A, Arduino RC, Johnson M, Achhra AC, Landay A, et al. Plasma levels of cytokines and chemokines and the risk of mortality in HIV-infected individuals: a case-control analysis nested in a large clinical trial. AIDS. 2015;29(7):847-851. 

4. Snell LM, Osokine I, Yamada DH, De la Fuente JR, Elsaesser HJ, Brooks DG. Overcoming CD4 Th1 Cell Fate Restrictions to Sustain Antiviral CD8 T Cells and Control Persistent Virus Infection. Cell Rep. 2016;16(12):3286-3296. 

5. Kornfeld H, Cruikshank WW. Prospects for IL-16 in the treatment of AIDS. Expert Opin Biol Ther. 2001.1(1):425-432. 

6. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev. 1992;56(1):152-179. 

7. Scala E, D’Offizi G, Rosso R, Turriziani O, Ferrara R, Mazzone AM. C-C chemokines, IL-16, and soluble antiviral factor activity are increased in cloned T cells from subjects with long-term nonprogressive HIV infection. J Immunol. 1997;158(9):4485- 4492. 

8. Amiel C, Darcissac E, Truong MJ, Dewulf J, Loyens M, Mouton Y, et al. Interleukin-16 (IL-16) inhibits human immunodeficiency virus replication in cells from infected subjects, and serum IL-16 levels drop with disease progression. J Infect Dis. 1999;179(1):83-91. 

9. Zhou P, Goldstein S, Devadas K, Tewari D, Notkins AL. Human CD4+ cells transfected with IL-16 cDNA are resistant to HIV-1 infection: inhibition of mRNA expression. Nat Med. 1997;3(6):659-664